<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824874</url>
  </required_header>
  <id_info>
    <org_study_id>165DDI16002</org_study_id>
    <nct_id>NCT02824874</nct_id>
  </id_info>
  <brief_title>CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)</brief_title>
  <official_title>A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Effect of Sitagliptin on Pharmacokinetics of Lobeglitazone in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a pharmacokinetic drug interaction between
      lobeglitazone and sitagliptin in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy male subjects of twenty(20), following treatments are administered dosing in each
      period and wash-out period is a minimum of 10 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ of Lobeglitazone</measure>
    <time_frame>1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Css,max of Lobeglitazone</measure>
    <time_frame>1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Css,min of Lobeglitazone</measure>
    <time_frame>1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css,av of Lobeglitazone</measure>
    <time_frame>1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tss,max of Lobeglitazone</measure>
    <time_frame>1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Lobeglitazone</measure>
    <time_frame>1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F of Lobeglitazone</measure>
    <time_frame>1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vdss/F of Lobeglitazone</measure>
    <time_frame>1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fluctuation[(Css,max-Css,min)/Css,av] of Lobeglitazone</measure>
    <time_frame>1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>swing[(Css,max-Css,min)/Css,min] of Lobeglitazone</measure>
    <time_frame>1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>Group 1(Treatment A/Treatment B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO
Period 2: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO
Each treatment period was separated by a washout period of at least 10 dyas.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2(Treatment B/Treatment A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO
Period 2: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO
Each treatment period was separated by a washout period of at least 10 dyas.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvie Tab. 0.5mg</intervention_name>
    <description>Duvie Tab. 0.5mg*1T/day for 5days, QD, PO</description>
    <arm_group_label>Group 1(Treatment A/Treatment B)</arm_group_label>
    <arm_group_label>Group 2(Treatment B/Treatment A)</arm_group_label>
    <other_name>Lobeglitazone 0.5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvie Tab. 0.5mg + Januvia Tab. 100mg</intervention_name>
    <description>Duvie Tab. 0.5mg + Januvia Tab.100mg*1T/day for 5 dyas, QD, PO</description>
    <arm_group_label>Group 1(Treatment A/Treatment B)</arm_group_label>
    <arm_group_label>Group 2(Treatment B/Treatment A)</arm_group_label>
    <other_name>Lobeglitazone 0.5mg + Sitagliptin 100mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A healthy male whose age is over 19 years old when visiting for initial screening test

          2. Body mass index(BMI) between 17.5~30.5 kg/m^2 and the body weight must be over 55kg
             (Body mass index (BMI) = weight (kg) / height (m)^2)

          3. A male with no congenital or chronic disease in three years, no history of symptoms in
             internal treatment, or no knowledge in the area

          4. Due to the special characteristics of drugs, the participators must be qualified to do
             the clinical screening after examined through hematology test and blood chemistry
             analysis, urinary test, the electrocardiogram (ECG), and etc.

          5. The participants must be volunteered and sign in an informed consent document proven
             by Chonbuk National University IRB before joining a study to show that he was given
             informed the purpose of tests and the special characteristics of drugs.

          6. The participants must have an ability and willingness to participate throughout the
             entire trials

        Exclusion Criteria:

          1. A person who had a history or symptoms of clinically aware of blood, kidney, internal
             secretion, gastrointestinal, urinary system, cardiovascular, liver, mental, nercous,
             or allergic(except subclinical seasonal allergies that is not treated at injecion)
             desease.

          2. Who had a gistory of gastrointestinal related disease which can be affected the drug
             absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's
             disease) or surgeries (except a simple appendectomy or herniotomy)

          3. Who had following results after examination

             a. ALT or AST &gt; twice higher than normal value

          4. Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup
             of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (!2%)
             (125 mL) = 12g)

          5. Who participated other clinical test or took testing bioequivalence drugs in 3 months
             before the first clinical drug trial.

          6. Whose blood pressure ≤ 100 or ≥150(systolic blood pressure) or &lt; 60 or ≥ 100(diastolic
             blood pressure)

          7. Who had a medical history of alcohol and drug abuses.

          8. Who had taken a drug that has a control of metabolic rate (activatioh or inhibithion)
             in 30 days before the first taking of clinical testing durg.

          9. WHo smokes more than 20 eigarettes per day.

         10. Who took prescribed drugs or over-the-conuter durgs in 10 days before taking of very
             first clinical testing drug.

         11. Who participated in whole blood donation in 2 months before the first taking of
             clinical testing drugs or platelet donations in 1 month before the first taking to
             clinical testing drugs.

         12. Who has a potent to increase a danger by participating in the clinical trials or sho
             can interrupt interpretin test results by having serious or chronic medical and mental
             status or having issues in results of the screening examination.

         13. Who has a histroy of an extreme sensitivity of drugs that contain Rosiglitazone or
             dugs that have similar effect a Rosiglitazone(Pioglitazone), or drugs that contain the
             ingredients of Sitagliptin or thiazolidinediones drugs.

         14. Who has a serious heart failure or a congestive heart failure that must be
             drug-treated

         15. A patient with hepatopathy.

         16. A patient with wevere nephropathy.

         17. Who has diabetic ketoacidosis or a diaetic coma, or type 1 diabetes, or has history of
             acute metablic acidosis or ketoacidosis.

         18. A patient with serious infectious disease or severe injuries before and after a
             surgery.

         19. Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose
             malabsorption or genetic disorders.

         20. Test subjects who is not willing or unable to comply with guidelines described in this
             protocol.

         21. A person who is not determined unsuitable to participate in this test by the
             researchers.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>July 6, 2016</last_update_submitted>
  <last_update_submitted_qc>July 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

